scholarly journals Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis

Circulation ◽  
2010 ◽  
Vol 121 (25) ◽  
pp. 2740-2746 ◽  
Author(s):  
Ida Martinelli ◽  
Paolo Bucciarelli ◽  
Serena M. Passamonti ◽  
Tullia Battaglioli ◽  
Emanuele Previtali ◽  
...  
Author(s):  
Khalid Khan ◽  
Anuj Chaturvedi

Cerebral Venous Thrombosis (CVT) is an uncommon cause of stroke and is generally present with headache. It is very difficult to diagnose it in initial stage due to its widely varying clinical features, risk factors, radiological findings and outcomes. Early diagnosis of CVT and its treatment can reduce the disease progress, its burden and risk of acute and long-term complications including mortality. A 23-year-old male patient was admitted from casualty department with complaints of severe generalised headache and photophobia since one week and four episodes of Generalised Tonic Clonic Seizures (GTCS) with post-ictal confusion and drowsiness since two days. All investigations were insignificant for the cause except that he was a sickle cell trait (AS pattern), that lead to CVT related headache and convulsion. He was treated with hydration in the form of intravenous fluids, warfarin, mannitol and syrup glycerol, Tab. Sodium bicarbonate and Tab. Hydroxyurea.


2014 ◽  
Vol 13 (1) ◽  
pp. 68-71 ◽  
Author(s):  
Imad S. Khan ◽  
Travis R. Ladner ◽  
Komal F. Satti ◽  
Moneeb Ehtesham ◽  
Lori C. Jordan ◽  
...  

Cerebral sinus venous thrombosis (CSVT) is a relatively rare but potentially devastating disease. Medical management of CSVT with systemic anticoagulation has been the mainstay treatment strategy with these patients. However, some patients may not respond to this treatment or may present with very severe symptoms indicating more aggressive management strategies. The authors present the case of a pediatric patient who presented with severe CSVT, who underwent successful recanalization with endovascular tissue plasminogen activator (tPA) and abciximab. To the authors' knowledge there are no cases of endovascular thrombolysis for CSVT described in the literature in which abciximab has been used in conjunction with tPA. The authors also review the literature regarding the agents used and outcome in pediatric patients with CSVT after endovascular thrombolysis. The use of abciximab in conjunction with tPA may be considered in patients whose blood is hypercoagulable and in whom the treatment strategy is to obtain acute recanalization and long-term venous patency. However, the use of adjunctive agents increases the risk of hemorrhagic complications and must be done judiciously.


Author(s):  
Isabella Herman ◽  
Cemal Karakas ◽  
Troy A. Webber ◽  
Stephen F. Kralik ◽  
Danielle S. Takacs ◽  
...  

2004 ◽  
Vol 40 (1-2) ◽  
pp. 53-55 ◽  
Author(s):  
C Barnes ◽  
F Newall ◽  
J Furmedge ◽  
M Mackay ◽  
P Monagle

Sign in / Sign up

Export Citation Format

Share Document